Settlement Round-Up

A round-up of significant securities class action settlements in the first quarter of 2011:

(1) Credit Suisse Group (NYSE: CS), a Switzerland-based financial services company, agreed to settle the securities class action pending against the company in the S.D. of New York. The case, originally filed in April 2008, stems from allegations that Credit Suisse made materially false statements regarding its mortgage-related exposure. The settlement is for $70 million. The D&O Diary has a detailed post.

(2) Tremont Group Holdings, Inc., a New York-based investment manager that is a subsidiary of Massachusetts Mutual Life Insurance Co., agreed to settle the securities litigation pending against the company in the S.D. of New York. The cases, originally filed starting in December 2008, stem from allegations that Tremont made material misstatements regarding the due diligence that was conducted on investment vehicles run by Bernard L. Madoff, to which Tremont transferred a substantial portion of its investment capital.

The partial settlement, which is for $100 million, resolves class action and derivative lawsuits. Additional money from Tremont will be added to the settlement fund following the wind-down of the company’s operations. Class members also may receive a portion of any recovery Tremont obtains from claims against third parties. Reuters has an article on the settlement.

(3) Satyam Computer Services Ltd. (NYSE: SAY), an India-based global business and information technology services company, now doing business as Mahindra Satyam, agreed to settle the securities class action pending against the company in the S.D. of New York. The case, originally filed in January 2009, stems from allegations that Satyam and its two top executives issued materially false financial statements by, among other things, inflating the company’s revenue and understating its debt.

The settlement, which is for $125 million, resolves only the claims against Satyam and does not include claims against other defendants in the suit. Satyam also agreed to pay class members 25% of any net recovery that the company may in the future obtain based on claims against PricewaterhouseCoopers LLP or its subsidiaries. Bloomberg has an article on the settlement.

Leave a comment

Filed under Settlement

Picking Sides

The U.S. Court of Appeals for the Third Circuit has weighed in on two controversial issues concerning loss causation and scheme liability. In In re DVI, Inc. Sec. Litig., 2011 WL 1125926 (3rd Cir. March 29, 2011), the court examined the lower court’s decision to grant class certification, except as to the claims against the company’s outside law firm. The key holdings are:

(1) Loss causation – The court addressed the issue currently before the U.S. Supreme Court in the Halliburton case, i.e., does a plaintiff have to establish loss causation to obtain class certification. In agreement with the Second Circuit and Seventh Circuit (but contrary to the Fifth Circuit), the court held that “a plaintiff need not demonstrate loss causation as a prerequisite to invoking the fraud-on-the-market presumption of reliance.” Instead, the burden is on the defendant to introduce evidence “demonstrating an allegedly corrective disclosure did not move the market – that there was no market impact and therefore no loss causation” which “may in some circumstances rebut the presumption of reliance.”

(2) Scheme liability – The plaintiffs argued that the Stoneridge decision created a “remoteness test” for assessing whether investors had relied on the fraudulent conduct of secondary actors. The remoteness test allegedly requires courts to assess: (a) the defendant’s level of involvement in the fraudulent scheme, (b) whether the misrepresentation was the “necessary or inevitable” result of the defendant’s conduct, and (c) whether the defendant’s conduct took place in the “investment sphere.” Like the Second Circuit, the court rejected this argument, finding that the only issue was whether the deceptive conduct “has been publicly disclosed and attributed to the actor.” In the instant case, because the plaintiffs did “not contend that the outside law firm’s role in masterminding the fraudulent 10-Q was disclosed to the public, they cannot invoke the [fraud-on-the-market presumption of reliance].”

Holding: Judgment affirmed.

Leave a comment

Filed under Appellate Monitor

Two From The NYLJ

The New York Law Journal has two securities litigation columns this week.

(1) In Lower Courts Divided on Standard for Pleading Loss Causation Post-Dura (3/31/11 – subscrip. req’d), the authors discuss the split over whether loss causation is merely subject to notice pleading (FRCP 8(a)(2)) or must be plead with particularity (FRCP 9(b)). The Supreme Court, in its Dura decision, left the issue open and no subsequent judicial consensus has emerged.

(2) In Most ARS Suits Tripped Up By Difficult Pleading Hurdles (3/31/11 – subscrip. req’d), the author examines what has happened to the flurry of securities class actions that were filed in the wake of the 2008 disruption in the market for auction rate securities. Most of the cases have been dismissed for failing to adequately plead various elements of a securities fraud claim, including scienter, loss causation or reliance.

Leave a comment

Filed under All The News That's Fit To Blog

Matrixx Decided

In the Matrixx Initiatives v. Siracusano case, the U.S. Supreme Court has held that the plaintiffs were not required, in a case alleging that Matrixx failed to disclose reports of a possible link between its leading drug product and the loss of smell, to plead that these reports were statistically significant. The unanimous decision authored by Justice Sotomayor rejects the use of statistical significance as a “bright-line rule” for the assessment of materiality in this type of case.

The core of the defendants’ argument was that in the absence of statistical significance, adverse event reports suggesting that a drug has caused a loss of smell do not “reflect a scientifically reliable basis for inferring a potential causal link” that would be material to a reasonable investor. The Court declined to hold, however, that “statistical significance is the only reliable indication of causation.” For example, the FDA relies on a wide range of evidence of causation and “sometimes acts on the basis of evidence that suggests, but does not prove, causation.” If “medical professionals and regulators act on the basis of evidence that is not statistically significant, it stands to reason that in certain cases reasonable investors would as well.”

Having rejected the proposed bright line rule, the Court found that the complaint adequately alleged “Matrixx received information that plausibly indicated a reliable causal link” between the drug and the loss of smell. The information included the adverse event reports and studies suggesting a causal link. In turn, investors would have viewed this information as material because it suggested there was “a significant risk to the commercial viability of Matrixx’s leading product,” especially because the risk associated with the drug (possible loss of smell) substantially outweighed the benefit of using the drug (alleviate cold symptoms). The omitted material information rendered Matrixx’s statement that its “revenues were going to rise 50 and then 80 percent” misleading.

Holding: Reversal of dismissal affirmed (the court also found that the plaintiffs had adequately plead scienter).

Notes on the Decision:

(1) The decision is quite narrow. Perhaps most importantly, the Court did not offer any redefinition of the Basic materiality standard (so the forests are safe). Nor did the Court make any broad pronouncements on the appropriateness of evaluating materiality at the motion to dismiss stage of a case.

(2) In line with its Tellabs decision on the issue of pleading scienter, the Court emphasized a holistic approach to evaluating the plaintiffs’ materiality allegations (e.g., “Viewing the allegations of the complaint as a whole . . .”).

Leave a comment

Filed under Appellate Monitor

Avoiding The Toll

And now for something a bit technical (but still important). The federal securities laws have statutes of repose (suit barred after a fixed number of years from the time the defendant acts in some way) and statutes of limitations (establishing a time limit for a suit based on the date when the claim accrued). Does the existence of a class action toll the statute of repose for a federal securities claim?

Under what is known as American Pipe tolling, “the commencement of a class action suspends the applicable statute of limitations as to all asserted members of the class who would have been parties had the suit been permitted to continue as a class action.” American Pipe & Construction Co. v. Utah, 414 U.S. 538, 554 (1974). The Supreme Court found that its rule was “consistent both with the procedures of [Federal Rule of Civil Procedure] 23 and with the proper function of limitations statutes.” Id. at 555. In a later case, however, the Supreme Court also found that federal statutes of repose are not subject to equitable tolling. Lampf, Pleva, Lipkind, Prupis & Pettigrow v. Gilbertson, 501 U.S. 350, 364 (1991). In attempting to reconcile these two cases, the majority of lower courts have concluded that American Pipe tolling applies to statutes of repose for federal securities claims because it is based on FRCP 23 and, therefore, is a type of legal (as opposed to equitable) tolling.

In Footbridge Ltd. Trust v. Countrywide Financial Corp., 2011 WL 907121 (S.D.N.Y. March 16, 2011), however, the court strongly disagreed with this analysis. The court addressed claims subject to the ’33 Act’s one-and-three-year limitations and repose provision that were brought more than three years after the relevant acts. The plaintiffs argued that the repose period was tolled by certain class actions asserting similar claims. The court concluded that “nowhere in American Pipe does the Court read the text of [FRCP] 23 as having embedded within it language that creates a class action tolling rule.” In the court’s view, American Pipe tolling is best understood as a judicially-created rule based on equitable considerations and, as a result, cannot extend a statute of repose. The court granted defendants’ motion for summary judgment.

Whether other courts will agree with the Footbridge decision remains to be seen. The potential impact of the ruling, however, is significant, especially in light of how long it can take a securities class action to get through the class certification stage (although securities fraud claims have a longer, five-year statute of repose). Could it lead to more individual suits?

Leave a comment

Filed under Summary Judgment

Monday Madness

Two interesting decisions from this past Monday.

(1) Just when it looked like the U.S. Supreme Court would never again reject a securities litigation cert petition, it turned down the Apollo Group case. The Ninth Circuit’s decision exacerbated a circuit split and presented an important loss causation issue. So why didn’t the Court grant cert? Perhaps securities litigation fatigue has set in.

Quote of note (Jones Day memo): “The five circuits that have addressed the timing of the loss are divided. The Second and Third Circuits have held that a securities-fraud plaintiff must demonstrate that the market immediately reacted to the corrective disclosure. Conversely, the Fifth, Sixth, and Ninth Circuits have held that the price decline may occur weeks or even months after the initial corrective disclosure. By denying certiorari in Apollo Group, the Supreme Court left this split unresolved.”

(2) Yet another cautionary tale about the use of confidential witnesses in securities class actions was issued by a court in the N.D. of Illinois. In City of Livonia Employees’ Retirement System v. Boeing Co., Civil Action No. 09 C 7143 (N.D. Ill. March 7, 2011), the court granted Boeing’s motions to dismiss for failure to state a claim and fraud on the court. In their second amended complaint, the plaintiffs had added allegations providing details about a confidential witness and the basis for this witness’ supposed knowledge of Boeing’s misconduct. The court expressly relied on these new allegations in finding that the plaintiffs had adequately plead scienter. After discovery began, however, it turned out that the confidential witness denied being the source of the allegations in the complaint, denied having worked for Boeing, and claimed to have never met plaintiffs’ counsel until his deposition. The court was not amused.

Quote of note: “If these facts were disclosed while the dismissal motions were pending, the court would not have concluded that the confidential source allegations were reliable, much less cogent and compelling. The second amended complaint would have been dismissed, possibly with prejudice, as insufficient under the PSLRA. It matters not whether, as plaintiffs argue, [the confidential witness] told their investigators the truth, but he is lying now for ulterior motives. The reality is that the informational basis for [the confidential witness allegations] is at best unreliable and at worst fraudulent, whether it is [the confidential witness] or plaintiffs’ investigators who are lying.”

Leave a comment

Filed under Appellate Monitor, Motion To Dismiss Monitor

The Comments Are In

Section 929Y of the Dodd-Frank Act directs the SEC to solicit public comments and thereafter conduct a study to determine the extent to which private rights of action under the antifraud provisions of the federal securities laws should be extended to cover transnational securities fraud. In other words, to what extent is the Supreme Court’s National Australia Bank decision a problem and what, if anything, should Congress do about it?

The SEC solicited comments back in October and the results are now available on the SEC’s website. They make for interesting reading. The commentators include current litigants in cases with extraterritoriality issues, forty-two law professors, the U.S. Chamber of Commerce, the governments of Australia and France, and an individual foreign investor who states that he has “been duped of huge sum of my life long savings by so called private bankers who are affiliates outside USA of US banks.”

Quote of note (Comments by Forty-Two Law Professors): “We differ in our views of private rights of action: some of us have significant doubts about the efficacy of securities class actions, while others believe shareholder litigation rights should be strengthened. Nevertheless, as a group we believe reform efforts should be applied consistently and logically to both domestic and affected foreign issuers, and we therefore support extending the test set forth in Section 929P of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 to private plaintiffs.”

Leave a comment

Filed under All The News That's Fit To Blog

After The Vivendi Verdict

A trial verdict that results in $9.3 billion in potential damages is likely to engender a slew of post-trial motions. The court’s decision on those motions in the Vivendi securities class action was made public this week.

The media focus has been on the court’s application of the National Australia Bank (NAB) decision to dismiss the fraud claims by purchasers (including U.S. purchasers) of Vivendi shares on foreign exchanges. The dismissal was in line with other post-NAB cases, although the Vivendi court was quick to point out that the Supreme Court’s decision contains imprecise language. In particular, on the issue of whether the decision permits, based on the existence of a dual listing (U.S. and foreign exchange), a U.S. cause of action for investors who purchased their shares on the foreign exchange, the court suggested that “perhaps Justice Scalia simply made a mistake.” That is to say, “[Scalia] stated the test as being whether the alleged fraud concerned the purchase or sale of a security ‘listed on an American stock exchange,’ when he really meant to say a security ‘listed and traded’ on a domestic exchange.” In any event, there was no indication that the Supreme Court “read Section 10(b) as applying to securities that may be cross-listed on domestic and foreign exchanges, but where the purchase and sale does not arise from the domestic listing.”

The Vivendi court’s other rulings are at least as interesting and two of them stand out.

(1) Corporate scienter – The court addressed how the jury could have found that Vivendi acted with scienter in committing securities fraud, while dismissing the claims against Vivendi’s former CEO and CFO. The court agreed that to prove corporate scienter, the plaintiffs needed to establish that a Vivendi agent committed a culpable act with scienter. However, the court found, the “fact that the jury absolved [the former officers] of liability does not negate the fact that there was sufficient evidence in the record in the first instance to enable a reasonable jury to find against all three defendants on the issue of scienter, thereby foreclosing judgment as a matter of law in Vivendi’s favor.” As to whether the verdicts were inconsistent, which is a possible ground for a new trial, the court concluded that “significant evidence admitted against Vivendi, but not against [the former officers], could have led the jury to find that plaintiffs proved that Vivendi violated Section 10(b) based on the scienter of [the former officers], even if the jury was unable to conclude the plaintiffs had met their burden of proof against [the former officers].”

(2) Reliance – The court noted that “certain means of rebutting the presumption of reliance require an individualized inquiry into the buying and selling decisions of particular class members.” Vivendi should have the opportunity to make this rebuttal as to individual class members, perhaps even through separate jury trials if necessary, although the exact procedures for the “individual reliance phase” would have to be determined. As a result, the court declined to enter a final judgment in the case.

Holding: Dismissed claims brought by purchasers of ordinary shares (as opposed to American Depositary Shares). Denied Vivendi motion for judgment as a matter of law or, in the alternative a new trial, except as to one statement. Denied entry of final judgment.

Leave a comment

Filed under Motion To Dismiss Monitor

Waking the Tiger

Item 303(a) of Regulation S-K, which requires issuers to disclose known trends or events “reasonably likely” to have a material effect on operations, capital, and liquidity, has been referred to as the “sleeping tiger” of securities litigation. Item 303(a) certainly has two attributes that are attractive to plaintiffs: it requires the issuer to offer a prediction on the effects of a known trend, but the disclosure arguably is not subject to the PSLRA’s safe harbor for forward-looking statements (other than two subsections dealing with off-balance sheet arrangements and contractual obligations). The use of Item 303(a) in securities litigation has a mixed history, but the Second Circuit may have woken the tiger last week.

In Litwin v. The Blackstone Group, L.P., 2011 WL 447050 (2d Cir. Feb. 10, 2011), the court considered whether the plaintiffs had adequately alleged that Blackstone failed to make required disclosures under Item 303(a) related to two portfolio companies and its real estate investment funds. The claims were brought pursuant to Section 11 and 12 of the ’33 Act, based on omissions in Blackstone’s registrations statement and prospectus, so the applicable pleading standard was notice pleading (i.e., enough facts that the claim is plausible on its face). Moreover, there was no dispute that there was a downturn in the real estate market at the time of Blackstone’s IPO. Accordingly, the sole issue was the pleading of materiality.

The court made the following key holdings.

First, the court rejected Blackstone’s argument that it was not required to make an Item 303(a) disclosure because the downturn in the real estate market was already part of the “total mix” of information available to the market. While investors knew about the downturn, the “potential future impact [on Blackstone’s investments] was certainly not public knowledge.”
Second, the court declined to find that Blackstone was not required to disclose information about particular portfolio companies because the investments were relatively small and the gains or losses from the investments were aggregated at the fund level. To hold otherwise, the court found, would “effectively sanction misstatements in a registration statement or prospectus related to particular portfolio companies so long as the net effect on the revenues of a public private equity firm like Blackstone was immaterial.” Moreover, the portfolio company investments were in key sectors of Blackstone’s business.

Finally, the court held that the plaintiffs were not required to identify specific real estate investments that had been adversely effected by the downturn. Indeed, that was the exact information, along with potential effect of the downturn, that the plaintiffs claimed was omitted. In any event, the plaintiffs had alleged enough facts connecting the real estate downturn with potential adverse effects on Blackstone’s real estate investments to state a plausible claim.

So what impact will the Blackstone decision have? At a minimum, the decision seems likely to encourage the use of Item 303(a) as a vehicle for private securities litigation, although obviously not every case is amenable to an allegation that there was a known, undisclosed trend. Second, the decision can be read to create a low materiality threshold (although this case did not allege fraud and therefore was not subject to the heightened pleading standard of Rule 9(b)). While the district court relied heavily on the fact that the investment losses did not have a significant impact on Blackstone’s overall financial results, the Second Circuit applied a more holistic, “what would a reasonable investor want to know,” standard. Of course, the Supreme Court soon will be weighing in on the issue of materiality. Stay tuned.

Holding: Dismissal vacated and remanded for further proceedings.

Leave a comment

Filed under Motion To Dismiss Monitor

MF Global Settles

MF Global Holdings Ltd. (NYSE: MF), a New York-based broker-dealer, has announced the preliminary settlement of the securities class action pending against the company in the S.D. of New York. The case, originally filed in March 2008, stems from allegations that the registration statement and prospectus issued by MF in connection with its July 2007 initial public offering were materially false and misleading because, among other things, it misrepresented the company’s risk-management policies, procedures and systems.

The settlement is for $90 million, of which $2.5 million will be paid by MF and $32.5 mllion will be paid by MF’s former parent company, Man Group PLC. MF’s claim for insurance coverage against the loss remains pending. Bloomberg has an article.

Leave a comment

Filed under Settlement